News Releases

 
News Releases
  Date Title and Summary View
Jan 8, 2018
MOUNTAIN VIEW, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced the appointment of William (Bill) Fairey as Executive Vice President and Chief Operating Officer. In this newly created posi...
Jan 4, 2018
-- ChemoCentryx to Receive $50 Million Milestone from Vifor Pharma for Validation of Conditional Marketing Authorization Application for Avacopan for the Treatment of ANCA Vasculitis -- -- Company Also Enters into $50 Million Growth Capital Financing Agreement with Hercules Capital -- MOUNTAIN VIEW, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -...
Jan 4, 2018
Conditional marketing authorization application for treatment of patients with ANCA-associated vasculitis validated for start of procedure by EMASignificant milestone further strengthens Kidney Health AllianceChemoCentryx to receive regulatory milestone payment from VFMCRP VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA AND CHEMOCENTRYX ANNOUNCE THAT TH...
Jan 3, 2018
MOUNTAIN VIEW, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare ...
Nov 17, 2017
MOUNTAIN VIEW, Calif., Nov. 17, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Piper Jaffra...
Nov 7, 2017
-- Phase III ADVOCATE trial of avacopan remains on track to complete enrollment in mid-2018 -- -- Patient enrollment ongoing in registration-supporting trial for avacopan in the treatment C3 Glomerulopathy (C3G) -- -- Plan to launch registration-supporting trial for CCX140 in the treatment of Focal Segmental Glomerulosclerosis (FSGS) in the f...
Nov 3, 2017
-- Rapid reduction in kidney inflammation following avacopan treatment in patients with ANCA-Associated Vasculitis revealed by analysis of markers of kidney damage -- -- Podocyte protection demonstrated with CCR2 inhibitor CCX140, supporting differentiated potential treatment option for patients with Focal Segmental Glomerulosclerosis -- MOUN...
Nov 1, 2017
MOUNTAIN VIEW, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that the Company's third quarter 2017 financial results will be released after market close on Tuesday, November 7, 2017. Ch...
Sep 5, 2017
MOUNTAIN VIEW, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at three upcoming investor conferences in...
Aug 8, 2017
-- Pivotal Phase III ADVOCATE trial of avacopan on track to complete enrollment in mid-2018 as projected -- -- Launching second trial of avacopan in patients with C3 Glomerulopathy (C3G) -- -- Conference call today at 5:00 p.m. Eastern Time -- MOUNTAIN VIEW, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a b...
Page:
1
... NextLast
= add release to Briefcase